Domestic Trademark Acquired for Combination Cancer Immunotherapy 'SynerTri Immunotherapy®'

Key facts

  • Domestic Trademark Acquired for Combination Cancer Immunotherapy 'SynerTri Immunotherapy®'
  • A medical group providing precision cancer medicine based on genomic information has acquired the domestic trademark for its combination cancer immunotherapy, 'SynerTri Immunotherapy®'. This move strengthens the branding and intellectual property protection of their personalized treatment strategy.
  • Source: PR Times
  • Date: April 16, 2026

Direct answer

A medical group providing precision cancer medicine based on genomic information has acquired the domestic trademark for its combination cancer immunotherapy, 'SynerTri Immunotherapy®'. This move strengthens the branding and intellectual property protection of their personalized treatment strategy.

Citation
Domestic Trademark Acquired for Combination Cancer Immunotherapy 'SynerTri Immunotherapy®' (April 16, 2026), PR Times
Source
PR Times
Date
April 16, 2026
A medical group providing precision cancer medicine based on genomic information has acquired the domestic trademark for its combination cancer immunotherapy, 'SynerTri Immunotherapy®'. This move strengthens the branding and intellectual property protection of their personalized treatment strategy.
その他NQ 0/100出典：PR Times

📋 Article Processing Timeline

  • 📰 Published: April 16, 2026 at 14:05
  • 🔍 Collected: April 16, 2026 at 14:31 (26 min after Published)
  • 🤖 AI Analyzed: April 19, 2026 at 00:52 (58h 20m after Collected)
Our group provides Precision Oncology based on genomic information. Based on the genomic information, which is the blueprint of cancer, we determine immunotherapy and molecularly targeted drugs and propose a treatment strategy optimized for each patient. Experts from various fields have come together to actively disseminate medical information along with the popularization of advanced medical care in the private practice sector.

FAQ

What is the registered domestic trademark acquired by the group?

The group has acquired a domestic trademark for the combination cancer immunotherapy named 'SynerTri Immunotherapy®'.

What type of oncology does the group provide to its patients?

The group provides Precision Oncology, which is determined based on genomic information.

How does the group propose a treatment strategy optimized for each patient?

They determine immunotherapy and molecularly targeted drugs based on genomic information to propose the treatment strategy.

What does the group refer to as the blueprint of cancer?

The group refers to genomic information as the blueprint of cancer.

Who has come together to actively disseminate medical information?

Experts from various fields have come together to actively disseminate medical information.

Back to Newsroom (8)